Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
FiercePharma21h
Fierce Pharma Asia—Merck and BioNTech's I-O bispecific buys; AZ CEO's China defense
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...
Merck receives CHMP opinion recommending approval of Keytruda
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
Germany’s Merck Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...
Yicai Global1d
Merck, Five Other Foreign Pharma Firms Get Nod to Offer Stem Cell, Gene Therapies in Shanghai FTZ
(Yicai) Nov. 15 -- The Germany’ Merck and five other overseas pharmaceutical companies have been given the green light to ...